LCB-14 is under clinical development by Iksuda Therapeutics and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LCB-14’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LCB-14 is under development for the treatment of solid tumors including HER2 positive metastatic breast cancer, non-small cell lung cancer, gastric cancer, adenocarcinoma of the gastroesophageal junction, metastatic colorectal cancer, ovarian cancer and ulcerative colitis, urothelial carcinoma, biliary tract cancer, pancreatic cancer, ovarian cancer, endometrial cancer and colorectal cancer. It is administered through intravenous route. The drug candidate is an antibody drug conjugate. It acts by targeting cells expressing human epidermal growth factor receptor 2 (HER2). It is developed based on ConjuAll or ADC Platform Technology.
Iksuda Therapeutics overview
Iksuda Therapeutics (Iksuda), formerly Glythera is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company develops antibody-based therapies for the treatment of cancer and broader based therapeutics. It uses its proprietary linker and stable glycan technologies permalink and premacarb to deliver solutions for development and manufacture efficacious and safe biologics to improve half-life and optimize bio-availability. The company partners with various biotech companies for its technology development activities. Iksuda is headquartered in Newcastle upon Tyne, Tyne and Wear, the UK.
For a complete picture of LCB-14’s drug-specific PTSR and LoA scores, buy the report here.